Intensity-Modulated Radiation Therapy Alone Versus Intensity-Modulated Radiation Therapy and Brachytherapy for Early-Stage Oropharyngeal Cancers: Results From a Randomized Controlled Trial

医学 临床终点 放射治疗 随机对照试验 近距离放射治疗 核医学 阶段(地层学) 内科学 随机化 泌尿科 生物 古生物学
作者
Ashwini Budrukkar,Vedang Murthy,Sheetal Kashid,Monali Swain,Venkatesh Rangarajan,Sarbani Ghosh Laskar,Sadhana Kannan,Shrikant Kale,Ritu Raj Upreti,Prathamesh Pai,Gouri Pantvaidya,Tejpal Gupta,Jai Prakash Agarwal
出处
期刊:International Journal of Radiation Oncology Biology Physics [Elsevier BV]
卷期号:118 (5): 1541-1551 被引量:8
标识
DOI:10.1016/j.ijrobp.2023.08.056
摘要

Purpose The objective of this study was to compare clinical outcomes of intensity-modulated radiation therapy (IMRT) alone versus IMRT + brachytherapy (BT) in patients with T1-T2N0M0 oropharyngeal squamous cell cancers (OPSCC). Methods and Materials This open-label randomized controlled trial was conducted at Tata Memorial Hospital, Mumbai, India. Patients with stage I and II OPSCC were considered for IMRT to a dose of 50 Gy/25 fractions/5 weeks in phase I followed by randomization (1:1) to further treatment with IMRT (20 Gy/10 fractions/2 weeks) or BT (192Ir high dose rate, 21 Gy/7 fractions/2 fractions per day). The primary endpoint of the trial was the reduction in xerostomia at 6 months evaluated using 99mTc salivary scintigraphy. Severe salivary toxicity (xerostomia) was defined as posttreatment salivary excretion fraction ratio <45%. Secondary endpoints were local control, disease-free survival, and overall survival. Results Between November 2010 and February 2020, 90 patients were randomized to IMRT (n = 46) alone or IMRT + BT (n = 44). Eleven patients (8 residual/recurrent disease, 2 lost to follow-up, 1 second primary) in the IMRT arm and 9 patients (8 residual/recurrence, 1 lost to follow-up) in the BT arm were not evaluable at 6 months for the primary endpoint. At 6 months, xerostomia rates using salivary scintigraphy were 14% (5/35: 95% CI, 5%-30%) in the BT arm while it was seen in 44% (14/32: 95% CI, 26%-62%) in the IMRT arm (P = .008). Physician-rated Radiation Therapy Oncology Group grade ≥2 xerostomia at any time point was observed in 30% of patients (9/30) in the IMRT arm and 6.7% (2/30) in the BT arm (P = .02). At a median follow-up of 42.5 months, the 3-year local control in the IMRT arm was 56.4% (95% CI, 43%-73%) while it was 66.2% (95% CI, 53%-82%) in the BT arm (P = .24). Conclusions The addition of BT to IMRT for T1-T2N0M0 OPSCC results in a significant reduction in xerostomia. This strongly supports the addition of BT to IMRT in suitable cases. The objective of this study was to compare clinical outcomes of intensity-modulated radiation therapy (IMRT) alone versus IMRT + brachytherapy (BT) in patients with T1-T2N0M0 oropharyngeal squamous cell cancers (OPSCC). This open-label randomized controlled trial was conducted at Tata Memorial Hospital, Mumbai, India. Patients with stage I and II OPSCC were considered for IMRT to a dose of 50 Gy/25 fractions/5 weeks in phase I followed by randomization (1:1) to further treatment with IMRT (20 Gy/10 fractions/2 weeks) or BT (192Ir high dose rate, 21 Gy/7 fractions/2 fractions per day). The primary endpoint of the trial was the reduction in xerostomia at 6 months evaluated using 99mTc salivary scintigraphy. Severe salivary toxicity (xerostomia) was defined as posttreatment salivary excretion fraction ratio <45%. Secondary endpoints were local control, disease-free survival, and overall survival. Between November 2010 and February 2020, 90 patients were randomized to IMRT (n = 46) alone or IMRT + BT (n = 44). Eleven patients (8 residual/recurrent disease, 2 lost to follow-up, 1 second primary) in the IMRT arm and 9 patients (8 residual/recurrence, 1 lost to follow-up) in the BT arm were not evaluable at 6 months for the primary endpoint. At 6 months, xerostomia rates using salivary scintigraphy were 14% (5/35: 95% CI, 5%-30%) in the BT arm while it was seen in 44% (14/32: 95% CI, 26%-62%) in the IMRT arm (P = .008). Physician-rated Radiation Therapy Oncology Group grade ≥2 xerostomia at any time point was observed in 30% of patients (9/30) in the IMRT arm and 6.7% (2/30) in the BT arm (P = .02). At a median follow-up of 42.5 months, the 3-year local control in the IMRT arm was 56.4% (95% CI, 43%-73%) while it was 66.2% (95% CI, 53%-82%) in the BT arm (P = .24). The addition of BT to IMRT for T1-T2N0M0 OPSCC results in a significant reduction in xerostomia. This strongly supports the addition of BT to IMRT in suitable cases.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
大模型的应助被魄罗bro采纳,获得10
刚刚
英俊的铭的应助被刘兆亮采纳,获得10
1秒前
1秒前
2秒前
Jun的应助被MARK11采纳,获得10
2秒前
2秒前
jiweibin完成签到,获得积分10
2秒前
jkkm发布了新的文献求助10
3秒前
猫南北发布了新的文献求助10
3秒前
4秒前
嗨皮牙发布了新的文献求助10
4秒前
5秒前
嘻嘻哈哈的应助被史萌采纳,获得10
5秒前
xiaosiallsa完成签到,获得积分10
5秒前
初景发布了新的文献求助100
5秒前
开朗的棒球完成签到,获得积分10
5秒前
6秒前
传奇3的应助被Viiigo采纳,获得10
6秒前
nienienie完成签到,获得积分10
6秒前
orixero的应助被zhang采纳,获得10
7秒前
白青发布了新的文献求助10
8秒前
linnea完成签到 ,获得积分10
8秒前
无花果的应助被DW采纳,获得10
8秒前
Mojoko完成签到,获得积分10
9秒前
9秒前
9秒前
123完成签到,获得积分10
10秒前
xueqili发布了新的文献求助10
10秒前
11秒前
Chris完成签到,获得积分10
11秒前
11秒前
勤奋苑睐完成签到,获得积分10
11秒前
12秒前
sunflower的应助被zsg采纳,获得10
13秒前
可靠的书桃完成签到,获得积分10
13秒前
qian72133完成签到,获得积分10
13秒前
13秒前
13秒前
dong666完成签到,获得积分10
14秒前
ttt完成签到,获得积分10
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8164136
求助须知:如何正确求助?哪些是违规求助? 9558106
关于积分的说明 21743732
捐赠科研通 7754719
什么是DOI,文献DOI怎么找? 3428449
关于科研通互助平台的介绍 2553081
邀请新用户注册赠送积分活动 2473097